Zooming out on AI in biopharma — with Vijay Pande
Zooming out on AI in biopharma — with Vijay Pande
Vijay Pande left Andreessen Horowitz this summer after 11 years as a life sciences investor. Now, he’s building a new firm focused on AI. He joins Post-Hoc Live to take the 10,000-foot view of AI in biotech and Silicon Valley: what do investors get right and wrong about biotech? What are the business models for AI in biopharma? Which moonshot project will stick? We’ll continue the conversation next week at Endpoints AI Day. Sign up for the virtual program here: https://events.endpoints.news/aida
Podcast 專家音訊節目
收錄於 888news Podcast 智庫專區，包含精華摘要與上市公司即時行情
Vijay Pande left Andreessen Horowitz this summer after 11 years as a life sciences investor. Now, he’s building a new firm focused on AI. He joins Post-Hoc Live to take the 10,000-foot view of AI in biotech and Silicon Valley: what do investors get right and wrong about biotech? What are the business models for AI in biopharma? Which moonshot project will stick? We’ll continue the conversation next week at Endpoints AI Day. Sign up for the virtual program here: https://events.endpoints.news/aiday2025